Agilent Betting Pharma Industry Will Adopt Comprehensive Asset-Management Programs | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Agilent officials believe that the comprehensive asset-management programs that it and a couple of key competitors have launched over the past couple of years are winning over a cost-conscious pharmaceutical industry, and will eventually be used by a growing number of large and mid-tier firms.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.